Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial

Abstract Background Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization for the prevention of malaria in pregnancy (MIP)-associated adverse outcomes in high burden areas. However, the efficacy of IPTp-SP has decrea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jean-Bertin Bukasa Kabuya, Matthew M. Ippolito, Jay Sikalima, Clifford Tende, Davies Champo, David Mwakazanga, Anna Marie P. Young, Modest Mulenga, Gershom Chongwe, Christine Manyando
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Malaria in pregnancy Intermittent presumptive therapy Zambia Sulfadoxine-pyrimethamine Dihydroartemisinin-piperaquine Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/af8458ce4d9f458eaa370cda25b379b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:af8458ce4d9f458eaa370cda25b379b2
record_format	dspace
spelling	oai:doaj.org-article:af8458ce4d9f458eaa370cda25b379b22021-11-21T12:31:06ZSafety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial10.1186/s13063-021-05745-01745-6215https://doaj.org/article/af8458ce4d9f458eaa370cda25b379b22021-11-01T00:00:00Zhttps://doi.org/10.1186/s13063-021-05745-0https://doaj.org/toc/1745-6215Abstract Background Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization for the prevention of malaria in pregnancy (MIP)-associated adverse outcomes in high burden areas. However, the efficacy of IPTp-SP has decreased in step with increasing parasite drug resistance. Suitable alternative strategies are needed. Methods This is a protocol for a phase IIIb open-label, two-armed randomized controlled superiority trial to assess the safety and efficacy of a hybrid approach to IPTp combining screening and treatment with dihydroartemisinin-piperaquine (DP) to the current IPTp-SP regimen at the first antenatal care clinic visit. Pregnant women without HIV infection and without signs or symptoms of malaria will be randomized to either standard IPTp-SP or hybrid IPTp-SP plus screening and treatment (IPTp-SP+). In the IPTp-SP+ arm, participants who screen positive by rapid diagnostic test for P. falciparum will be treated with DP at the first antenatal visit while those who screen negative will receive SP per current guidelines. All participants will be administered SP on days 35 and 63 and will be actively followed biweekly up to day 63 and then monthly until delivery. Infants will be followed until 1 year after delivery. The primary endpoint is incident PCR-confirmed MIP at day 42. Secondary endpoints include incident MIP at other time points, placental malaria, congenital malaria, hemoglobin trends, birth outcomes, and incidence of adverse events in infants up to the first birthday. Discussion A hybrid approach to IPTp that combines screening and treatment with an artemisinin-based combination therapy at the first visit with standard IPTp-SP is hypothesized to confer added benefit over IPTp-SP alone in a high malaria transmission area with prevalent SP resistant parasites. Trial registration Pan African Clinical Trials Registry 201905721140808 . Registered retrospectively on 11 May 2019Jean-Bertin Bukasa KabuyaMatthew M. IppolitoJay SikalimaClifford TendeDavies ChampoDavid MwakazangaAnna Marie P. YoungModest MulengaGershom ChongweChristine ManyandoBMCarticleMalaria in pregnancyIntermittent presumptive therapyZambiaSulfadoxine-pyrimethamineDihydroartemisinin-piperaquineMedicine (General)R5-920ENTrials, Vol 22, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Malaria in pregnancy Intermittent presumptive therapy Zambia Sulfadoxine-pyrimethamine Dihydroartemisinin-piperaquine Medicine (General) R5-920
spellingShingle	Malaria in pregnancy Intermittent presumptive therapy Zambia Sulfadoxine-pyrimethamine Dihydroartemisinin-piperaquine Medicine (General) R5-920 Jean-Bertin Bukasa Kabuya Matthew M. Ippolito Jay Sikalima Clifford Tende Davies Champo David Mwakazanga Anna Marie P. Young Modest Mulenga Gershom Chongwe Christine Manyando Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial
description	Abstract Background Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization for the prevention of malaria in pregnancy (MIP)-associated adverse outcomes in high burden areas. However, the efficacy of IPTp-SP has decreased in step with increasing parasite drug resistance. Suitable alternative strategies are needed. Methods This is a protocol for a phase IIIb open-label, two-armed randomized controlled superiority trial to assess the safety and efficacy of a hybrid approach to IPTp combining screening and treatment with dihydroartemisinin-piperaquine (DP) to the current IPTp-SP regimen at the first antenatal care clinic visit. Pregnant women without HIV infection and without signs or symptoms of malaria will be randomized to either standard IPTp-SP or hybrid IPTp-SP plus screening and treatment (IPTp-SP+). In the IPTp-SP+ arm, participants who screen positive by rapid diagnostic test for P. falciparum will be treated with DP at the first antenatal visit while those who screen negative will receive SP per current guidelines. All participants will be administered SP on days 35 and 63 and will be actively followed biweekly up to day 63 and then monthly until delivery. Infants will be followed until 1 year after delivery. The primary endpoint is incident PCR-confirmed MIP at day 42. Secondary endpoints include incident MIP at other time points, placental malaria, congenital malaria, hemoglobin trends, birth outcomes, and incidence of adverse events in infants up to the first birthday. Discussion A hybrid approach to IPTp that combines screening and treatment with an artemisinin-based combination therapy at the first visit with standard IPTp-SP is hypothesized to confer added benefit over IPTp-SP alone in a high malaria transmission area with prevalent SP resistant parasites. Trial registration Pan African Clinical Trials Registry 201905721140808 . Registered retrospectively on 11 May 2019
format	article
author	Jean-Bertin Bukasa Kabuya Matthew M. Ippolito Jay Sikalima Clifford Tende Davies Champo David Mwakazanga Anna Marie P. Young Modest Mulenga Gershom Chongwe Christine Manyando
author_facet	Jean-Bertin Bukasa Kabuya Matthew M. Ippolito Jay Sikalima Clifford Tende Davies Champo David Mwakazanga Anna Marie P. Young Modest Mulenga Gershom Chongwe Christine Manyando
author_sort	Jean-Bertin Bukasa Kabuya
title	Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial
title_short	Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial
title_full	Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial
title_fullStr	Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial
title_full_unstemmed	Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial
title_sort	safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (iptp-sp+): study protocol for a randomized controlled trial
publisher	BMC
publishDate	2021
url	https://doaj.org/article/af8458ce4d9f458eaa370cda25b379b2
work_keys_str_mv	AT jeanbertinbukasakabuya safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial AT matthewmippolito safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial AT jaysikalima safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial AT cliffordtende safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial AT davieschampo safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial AT davidmwakazanga safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial AT annamariepyoung safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial AT modestmulenga safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial AT gershomchongwe safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial AT christinemanyando safetyandefficacyofintermittentpresumptivetreatmentwithsulfadoxinepyrimethamineusingrapiddiagnostictestscreeningandtreatmentwithdihydroartemisininpiperaquineatthefirstantenatalcarevisitiptpspstudyprotocolforarandomizedcontrolledtrial
_version_	1718418963899088896

Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial

Ejemplares similares